Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Carnaxide
Clinical trial register · Portugal

Clinical Trials in Carnaxide, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1104 matching records held by the registry are in this view. Synced 30 Oct 2026, 03:17 UTC
1104
Studies in scope
all four open statuses
533
Recruiting now
open to new participants
285
Lead sponsors
across recruiting studies
Top sites
Lisbon 689 Porto 537 Coimbra 256 Braga 182 Vila Nova de Gaia 105
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Medtronic3 Novartis Pharmaceuticals3 Otsuka Pharmaceutical Development & Commercialization, Inc.2 Amgen2 Alnylam Pharmaceuticals2
Site location
Lisbon689 Porto537 Coimbra256 Braga182 Vila Nova de Gaia105
All 97 locations
Target enrolment
to

Trials with a site in Carnaxide

36 of 1104 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Portugal
Start
Recruiting
Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)
NCT07597291Cardiogenic Shock Acute, Cardiogenic Shock, Cardiogenic Shock Post Myocardial Infarction
Hospital de Santa Cruz, Portugal
Observational
800
Carnaxide
2026-06-10
Recruiting
Bayer
Phase 3
117
Coimbra, Carnaxide, Lisbon, Porto
2026-06-01
Recruiting
Fundación EPIC
Observational
960
Amadora, Carnaxide, Coimbra, Faro, Penafiel
2025-12-11
Recruiting
Bayer
Phase 3
111
Coimbra, Lisbon, Carnaxide, Porto
2025-11-19
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Almada, Baixa Da Banheira, Carnaxide, Coimbra, Creixomil, Leiria, Lisbon, Loures
2025-09-06
Active, closed
Amgen
Phase 3
12,800
Braga, Carnaxide, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Ponte de Lima, Riachos, Torres Novas
2025-07-25
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Carnaxide, Vila Franca de Xira, Vila Nova de Gaia
2025-07-16
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Carnaxide, Creixomil, Leiria, Lisbon, Vila Real, Viseu
2025-07-02
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Carnaxide
2025-05-15
Recruiting
Portuguese Registry With Meril Myval THV Series - MyPORTuVal Registry
NCT06818435Aortic Valve Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
Portuguese Association of Interventional Cardiology
Observational
150
Carnaxide, Coimbra, Evora, Lisbon, Porto
2025-05-13
Recruiting
Biogen
Phase 3
454
Carnaxide, Vila Nova de Gaia, Aveiro, Braga, Coimbra, Leiria, Setúbal
2025-05-08
Recruiting
VitaFlow LIBERTY Europe
NCT06535659Aortic Valve Stenosis
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Observational
222
Carnaxide
2025-05-06
Recruiting
Sanofi
Phase 2
84
Carnaxide, Lisbon, Porto
2024-12-19
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Aveiro, Braga, Carnaxide, Castelo Branco, Coimbra, Faro, Funchal, Lisbon
2024-08-30
Active, closed
Fundación EPIC
Observational
501
Carnaxide, Lisbon
2024-02-26
Active, closed
argenx
Phase 2
103
Carnaxide, Lisbon, Porto
2024-02-17
Recruiting
Abbott Medical Devices
Observational
1,000
Carnaxide, Lisbon
2023-09-29
Recruiting
The ReTAVI Prospective Observational Registry
NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction
Institut für Pharmakologie und Präventive Medizin
Observational
250
Carnaxide, Vila Nova de Gaia
2023-09-05
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Carnaxide, Lisbon
2023-09-01
Recruiting
P+F Products + Features GmbH
Not applicable
267
Lisbon, Carnaxide, Vila Nova de Gaia, Evora
2023-07-03
Active, closed
Boston Scientific Corporation
Observational
1,173
Carnaxide
2023-03-24
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Almada, Carnaxide, Coimbra, Lisbon, Matosinhos Municipality, Porto, Santa Maria da Feira, Setúbal
2023-03-09
Recruiting
Tampere University
Not applicable
12,000
Carnaxide, Lisbon
2023-02-01
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Braga, Carnaxide, Lisbon, Loures, Porto, Setúbal, Vila Franca de Xira, Vila Nova de Gaia
2022-05-30
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Braga, Carnaxide, Porto
2022-04-05
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Braga, Carnaxide, Lisbon, Porto
2022-03-15
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Alcabideche, Almada, Carnaxide, Coimbra, Guimarães, Leiria, Lisbon, Matosinhos Municipality
2021-11-23
Recruiting
Penumbra Inc.
Observational
1,500
Carnaxide
2021-06-25
Active, closed
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Medtronic Cardiovascular
Not applicable
1,103
Carnaxide
2021-04-02
Recruiting
Biosense Webster, Inc.
Observational
8,000
Carnaxide
2021-02-22
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Carnaxide, Torres Novas
2020-12-11
Recruiting
Meril Life Sciences Pvt. Ltd.
Not applicable
988
Carnaxide, Lisbon, Porto
2020-11-04
Recruiting
Occlutech International AB
Observational
150
Carnaxide, Lisbon
2020-10-28
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Carnaxide, Evora, Lisbon, Porto
2018-05-14
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Carnaxide, Creixomil, Lisbon, Porto, Santarém
2012-01
Recruiting
Medtronic
Observational
20,000
Carnaxide, Creixomil, Lisbon, Porto, Santarém
1983-01
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 31 October 2026. https://priyalifescience.com/clinical-trials-portugal/city/carnaxide

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,104 studies in total at the last sync on 30 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Carnaxide.

How many clinical trials are recruiting in Carnaxide?

23 of the 36 studies on this page are recruiting new participants as of the 30 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Carnaxide), 36 studies
PhaseStudiesRecruitingShare
Observational151141.7%
Phase 312633.3%
Not applicable5413.9%
Phase 2328.3%
Phase 2/3102.8%

Most active sponsors

Lead sponsors with the most studies (Carnaxide)
Lead sponsorStudiesRecruiting
Medtronic32
Novartis Pharmaceuticals30
Alnylam Pharmaceuticals22
Amgen21
Bayer22
Fundación EPIC21
Otsuka Pharmaceutical Development & Commercialization, Inc.20
Abbott Medical Devices11
argenx10
Biogen11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.